CN Patent

CN118317946A — 用于制备巴瑞替尼的方法和中间体

Assigned to Incyte Corp · Expires 2024-07-09 · 2y expired

What this patent protects

本公开涉及用于制备巴瑞替尼、其盐以及相关合成中间体化合物及其盐的方法。

USPTO Abstract

本公开涉及用于制备巴瑞替尼、其盐以及相关合成中间体化合物及其盐的方法。

Drugs covered by this patent

ruxolitinib-phosphate (RUXOLITINIB PHOSPHATE)

Patent Metadata

Patent number: CN118317946A
Jurisdiction: CN
Classification: —
Expires: 2024-07-09
Drug substance claim: No
Drug product claim: No
Assignee: Incyte Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.